Dr. Peng Chen 陈鹏
Chief Physician, Associate Professor
Department of Urology, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of urological tumors, with a focus on endoscopic minimally invasive surgery.
Dr. Chen is Deputy Director of Urology, Chief Physician, Associate Professor, and Master’s supervisor at Affiliated Cancer Hospital of Xinjiang Medical University. Dr. Chen graduated from Xinjiang Medical College in July 1991 and completed a one-year fellowship at Peking University People’s Hospital (1998–1999) with a CMB scholarship. Dr. Chen leads research projects, including one National Natural Science Foundation grant, and has published articles in domestic core journals.
Professional roles
- Member, Chinese Medical Association
- Member, China Anti-Cancer Association
- Professional Member, Chinese Society of Clinical Oncology (CSCO)
- Member, Xinjiang Anti-Cancer Association
Name order: in Chinese the family name comes first (Chen Peng). Papers usually list the name as Peng Chen or Chen P.
Selected publications
35 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Cell Mol Med, 2026 (senior author): ODC1 Polyamine Metabolism Drives Prostate Cancer via AKT and Splicing. PubMed 41803527
- Int J Surg, 2025 (senior author): POU5F1 upregulates SPP1 to sustain stem-like traits and malignant phenotypes via JAK1/STAT3 in clear cell renal cell carcinoma. PubMed 41403335
- Transl Androl Urol, 2024 (senior author): SPOP enhances FADD degradation and decreases the activeness of the NF-κB signaling pathway in prostate cancer: an in vitro study. PubMed 39816234
- J Transl Med, 2024 (senior author): Single-cell and spatial transcriptomics reveal SPP1-CD44 signaling drives primary resistance to immune checkpoint inhibitors in RCC. PubMed 39736762
- BMC Urol, 2024 (senior author): Relationship between circulating miRNA-222-3p and miRNA-136-5p and the efficacy of docetaxel chemotherapy in metastatic castration-resistant prostate cancer patients. PubMed 39709424
- J Transl Med, 2024 (senior author): Single-cell transcriptome sequencing reveals aberrantly activated inter-tumor cell signaling pathways in the development of clear cell renal cell carcinoma. PubMed 38191424
- Sci Rep, 2023 (senior author): Retrospective analysis of urinary tract stone composition in a Chinese ethnic minority colony based on Fourier transform infrared spectroscopy. PubMed 37596395
- Cell Biol Int, 2021 (senior author): Tumor-associated macrophage-derived CCL5 promotes chemotherapy resistance and metastasis in prostatic cancer. PubMed 34003531
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion